Your browser doesn't support javascript.
loading
Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis.
Childs, Daniel S; Le-Rademacher, Jennifer G; McMurray, Ryan; Bendel, Markus; O'Neill, Carrie; Smith, Thomas J; Loprinzi, Charles L.
Afiliação
  • Childs DS; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: childs.daniel@mayo.edu.
  • Le-Rademacher JG; Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota, USA.
  • McMurray R; Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota, USA.
  • Bendel M; Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • O'Neill C; Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Smith TJ; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland, USA.
  • Loprinzi CL; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
J Pain Symptom Manage ; 61(6): 1247-1253, 2021 06.
Article em En | MEDLINE | ID: mdl-33249081
ABSTRACT
CONTEXT Preliminary trials report that Scrambler Therapy, a form of electroanalgesia, may improve discomfort from chemotherapy-induced peripheral neuropathy (CIPN).

OBJECTIVE:

The objective of this phase II, randomized controlled trial was to evaluate the efficacy of Scrambler therapy vs. transcutaneous electrical nerve stimulation (TENS) in treating CIPN.

METHODS:

Fifty patients were accrued for the first half of this two-part, crossover trial consisting of a 2-week treatment period with either Scrambler or TENS, followed by an 8-week observation period, and then crossover treatment. Twenty-two patients proceeded to the crossover phase. The primary means of assessment was patient-reported outcomes, including symptom severity scales and Global Impression of Change questionnaires. Symptoms were assessed daily during the treatment period and weekly during an 8-week observation period.

RESULTS:

A 50% or greater reduction in primary symptom (pain or tingling) score on the last day of treatment was achieved by 6 of 10 Scrambler-treated patients (60%) and 3 of 12 TENS-treated patients (25%) after crossover (P = 0.11). By day 4 of treatment, the two arms diverged with respect to mean change in primary symptom score; this effect was largely carried through to the end of the two-week treatment period. Similarly, Scrambler therapy appeared better than TENS when assessed by Global Impression of Change for neuropathy, pain, and overall quality of life.

CONCLUSIONS:

Similar findings from the initial randomization and crossover phases of this study support further evaluation of the efficacy of Scrambler therapy in alleviating CIPN symptoms. Evaluation in a larger, randomized controlled trial with standardized treatment is warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Periférico / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Periférico / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article